Adrian M. Senderowicz
Independent DirectorDr. Adrian M. Senderowicz, M.D., had been an Independent Director of Anavex Life Sciences Corp. since September 24, 2026 until October 28, 2026. He serves as Member of Scientific Advisory Board at Triana Biomedicines, Inc. He served as Director at Oncoinvent AS since February 4, 2022. He serves as Senior Advisor at Constellation Pharmaceuticals, Inc. since June 22, 2020. He served as Senior Vice President and Chief Medical Officer at Constellation Pharmaceuticals, Inc. since July 18, 2017 until June 22, 2020. Dr. Senderowicz served as Senior Vice President and Chief Medical Officer of Cerulean Pharma Inc. from September 4, 2015 to June 15, 2017. He was Independent Director at Step Pharma SAS until 2026. He served as the Chief Medical Officer and Senior Vice President of Clinical Development and Regulatory Affairs at Ignyta, Inc. from August 2014 to April 2015 and was its Regulatory Strategy Officer from February 2015 to March 2015. Prior to joining Ignyta, he served as Vice President, Global Regulatory Oncology at Sanofi, a position he held from September 2013 to August 2014. Prior to Sanofi, he served as the Chief Medical Officer and Vice President of Medical Development at Tokai Pharmaceuticals, Inc. from August 9, 2012 to April 2013. He held positions of increasing responsibility, including Senior Medical Director of Oncology Clinical Development at AstraZeneca from August 2008 to March 2012 and Medical Director of Oncology from July 2008 to July 2009, where he was responsible for clinical development and regulatory programs for novel cancer therapeutics, including guiding the team through FDA approval of Caprelsa(R) (vandetanib) for patients with advanced medullary thyroid carcinoma. He served for the years as an Adjunct Professor in the Department of Biology at Temple University. Prior to AstraZeneca, Dr. Senderowicz held a variety of leadership positions at the U.S. FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research. He is a US Board certified medical oncologist and President of Oncology Drug Development, LLC. At the FDA, Dr. Senderowicz served as a Team Leader responsible for planning, coordinating and evaluating the division's various oncology medical programs. Also, Dr. Senderowicz was a Senior Medical Reviewer with the FDA's Division of Oncology, where he reviewed more than 100 submitted regulatory documents including Investigational New Drug applications, pre-Investigational New Drugs, New Drug Applications and Special Protocol Assessments. Dr. Senderowicz held a variety of clinical and research positions, including Coordinator of the Prostate Cancer Drug Development Clinic and Investigator and Chief, Molecular Therapeutics Unit, with the National Cancer Institute/National Institutes of Health. He received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC), an advanced and difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of androgen deprivation therapy. Dr. Senderowicz has been an Independent Director of Puma Biotechnology, Inc. since August 11, 2015. Dr. Senderowicz is currently a board member of Step Pharma. He completed his Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai and a Clinical Oncology Fellowship at the NCI. Dr. Senderowicz holds both M.D. and Instructor of Pharmacology degrees from the School of Medicine at the Universidad de Buenos Aires in Argentina.
公司職務
- 公司名稱Puma Biotechnology, Inc.股票代碼PBYI職務Independent Director共事同僚
- AHAlan H. AuerbachFounder, Chairman, President, CEO & Secretary
- MFMaximo F. NouguesCFO & Principal Accounting Officer
- DHDouglas HuntChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
- GGGordon G. EsplinChief Accounting Officer
- MOMariann OhanesianSenior Director of Investor Relations
- JMJay M. MoyesLead Independent Director
- TETroy Edward WilsonIndependent Director
- BMBrian M. StuglikIndependent Director
